{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:44:39Z","timestamp":1793400279541,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The appropriate use of Piperacillin\/Tazobactam (Pip\/Taz), including the correct dose, escalating and or de-escalation according to the microbiological culture is essential to reduce the antibiotic resistance. Resistant to antimicrobials in a major global problem and contributes significantly to morbidity, mortality and cost of care. Guidelines exists to ensure appropriate use of Pip\/Taz. Antibiotics Stewardship guidelines (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329404\/9789241515481-eng.pdf\">https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329404\/9789241515481-eng.pdf<\/jats:ext-link>) provides a detailed recommendation with regards to initiation, monitoring and escalation and de-escalation based on final culture results. Appling such guidelines ensures a more proper utilization of the empiric uses of antibiotics used in the hospital-based setting. Use of Pip\/Taz in cases of suspected infection postoperatively is common practice in the cardiac surgery ward where this study was conducted.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a prospective cohort study involving all patients who were admitted to the cardiac surgery unit of a tertiary care center. All patient prescribed at least 1 day of Pip\/Taz as an empirical therapy were included and prospectively observed. We aimed to evaluate the use of Pip\/Taz and its appropriateness based on Antibiotics Stewardship guidelines (ASG). Any deviation from the guidelines in initiation, escalation, de-escalation based on culture and sensitivity results was considered inappropriate use. Four patients died (1.3%) early as result of complications for surgery but included in the analysis. The study was conducted from October 2017 to October 2018.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 300 patients who received Pip\/Taz Cultures were done in 250 patients (83%). The overall appropriate use of Pip\/Taz was seen in 166 patients (55.3%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The empirical use of Pip\/Taz in the surgical cardiac unit was largely inappropriate and not entirely driven by the culture test results. Interventions are needed to optimize the use of Pip\/Taz including appropriate culture and sensitivity driven use and timely de-escalation or de-escalation when indicated. This will prevent emergence of resistance and reduce the patient toxicity and financial costs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13019-020-01109-y","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T09:02:42Z","timestamp":1588323762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prospective evaluating the appropriate use of piperacillin \/tazobactam in cardiac center of a tertiary care hospital"],"prefix":"10.1186","volume":"15","author":[{"given":"Sanaa Saeed","family":"Mekdad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leenah","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"issue":"2","key":"1109_CR1","first-page":"304","volume":"30","author":"K Machka","year":"1980","unstructured":"Machka K, Dickert H, Braveny I. In vitro activity of piperacillin compared with that of ampicillin, ticarcillin, azlocillin, and mezlocillin. Arzneimittelforschung. 1980;30(2):304\u20137.","journal-title":"Arzneimittelforschung"},{"key":"1109_CR2","first-page":"51","volume":"573","author":"TM File Jr","year":"1994","unstructured":"File TM Jr, Tan JS. Efficacy and safety of piperacillin\/tazobactam in skin and soft tissue infections. Eur J Surg Suppl. 1994;573:51\u20135.","journal-title":"Eur J Surg Suppl"},{"issue":"5","key":"1109_CR3","first-page":"319","volume":"51","author":"M Takamuro","year":"1998","unstructured":"Takamuro M, Watanabe A. Clinical studies on tazobactam\/piperacillin (YP-14) in the pediatric field. Jpn J Antibiot. 1998;51(5):319\u201324.","journal-title":"Jpn J Antibiot"},{"issue":"5","key":"1109_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/0009922808330774","volume":"48","author":"MC Di Pentima","year":"2009","unstructured":"Di Pentima MC, et al. Antimicrobial prescription errors in hospitalized children: role of antimicrobial stewardship program in detection and intervention. Clin Pediatr (Phila). 2009;48(5):505\u201312.","journal-title":"Clin Pediatr (Phila)"},{"issue":"9","key":"1109_CR5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1086\/677624","volume":"35","author":"JM Mehta","year":"2014","unstructured":"Mehta JM, et al. Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2014;35(9):1092\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1109_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/IDR.S30043","volume":"5","author":"A Pathak","year":"2012","unstructured":"Pathak A, et al. High prevalence of extended-spectrum beta-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India. Infect Drug Resist. 2012;5:65\u201373.","journal-title":"Infect Drug Resist"},{"issue":"Suppl 3","key":"1109_CR7","first-page":"S86","volume":"35","author":"B Ostrowsky","year":"2014","unstructured":"Ostrowsky B, et al. Lessons learned from implementing Clostridium difficile-focused antibiotic stewardship interventions. Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S86\u201395.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"1109_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jiph.2014.09.004","volume":"8","author":"JA Al-Tawfiq","year":"2015","unstructured":"Al-Tawfiq JA, et al. Restrictive reporting of selected antimicrobial susceptibilities influences clinical prescribing. J Infect Public Health. 2015;8(3):234\u201341.","journal-title":"J Infect Public Health"},{"issue":"2","key":"1109_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/03009734.2014.909911","volume":"119","author":"H Hanberger","year":"2014","unstructured":"Hanberger H, et al. Antibiotic consumption and antibiotic stewardshipin Swedish hospitals. Ups J Med Sci. 2014;119(2):154\u201361.","journal-title":"Ups J Med Sci"},{"issue":"3","key":"1109_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s15010-016-0885-z","volume":"44","author":"K de With","year":"2016","unstructured":"de With K, Allerberger F, Amann S. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44(3):395\u2013439.","journal-title":"Infection"},{"issue":"5","key":"1109_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/mdr.2015.0220","volume":"22","author":"E Cerceo","year":"2016","unstructured":"Cerceo E, et al. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22(5):412\u201331.","journal-title":"Microb Drug Resist"},{"issue":"9","key":"1109_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/11024159950189393","volume":"165","author":"B Ohlin","year":"1999","unstructured":"Ohlin B, et al. Piperacillin\/tazobactam compared with cefuroxime\/ metronidazole in the treatment of intra-abdominal infections. Eur J Surg. 1999;165(9):875\u201384.","journal-title":"Eur J Surg"},{"issue":"12","key":"1109_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1097\/CCM.0000000000001294","volume":"43","author":"Z Thomas","year":"2015","unstructured":"Thomas Z, et al. A multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States. Crit Care Med. 2015;43(12):2527\u201334.","journal-title":"Crit Care Med"},{"issue":"1","key":"1109_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ajic.2009.04.288","volume":"38","author":"P Rattanaumpawan","year":"2010","unstructured":"Rattanaumpawan P, Sutha P, Thamlikitkul V. Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures. Am J Infect Control. 2010;38(1):38\u201343.","journal-title":"Am J Infect Control"},{"issue":"4","key":"1109_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jiph.2017.09.001","volume":"11","author":"E Youssif","year":"2018","unstructured":"Youssif E, Aseeri M, Khoshhal S. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia. J Infect Public Health. 2018;11(4):486\u201390.","journal-title":"J Infect Public Health"},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/IDR.S27965","volume":"5","author":"FY Khan","year":"2012","unstructured":"Khan FY, et al. Evaluation of the use of piperacillin\/tazobactam (Tazocin) at Hamad general hospital, Qatar: are there unjustified prescriptions? Infect Drug Resist. 2012;5:17\u201321.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"1109_CR17","first-page":"E1","volume":"67","author":"DE Wiskirchen","year":"2018","unstructured":"Wiskirchen DE, et al. Inpatient antibiotic resistance: Everyone\u2019s problem. J Fam Pract. 2018;67(2):E1\u2013E11.","journal-title":"J Fam Pract"},{"issue":"3","key":"1109_CR18","first-page":"2","volume":"5","author":"S King","year":"2016","unstructured":"King S, et al. Antimicrobial stewardship: the effectiveness of educational interventions to change risk-related Behaviours in the general population: a systematic review. Rand Health Q. 2016;5(3):2.","journal-title":"Rand Health Q"},{"issue":"6","key":"1109_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bjid.2016.08.001","volume":"20","author":"KE Barber","year":"2016","unstructured":"Barber KE, et al. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs. Braz J Infect Dis. 2016;20(6):631\u20134.","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"1109_CR20","doi-asserted-by":"publisher","first-page":"ofy068","DOI":"10.1093\/ofid\/ofy068","volume":"5","author":"AV Gundlapalli","year":"2018","unstructured":"Gundlapalli AV, et al. Antimicrobial agent shortages: the new norm for infectious diseases physicians. Open Forum Infect Dis. 2018;5(4):ofy068.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 4","key":"1109_CR21","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1086\/500664","volume":"42","author":"RC Owens Jr","year":"2006","unstructured":"Owens RC Jr, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis. 2006;42(Suppl 4):S173\u201381.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1109_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0924-8579(03)00108-0","volume":"22","author":"DM Livermore","year":"2003","unstructured":"Livermore DM, et al. In vitro activity of piperacillin\/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents. 2003;22(1):14\u201327.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1109_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2009.06.022","volume":"65","author":"RN Jones","year":"2009","unstructured":"Jones RN, et al. Antipseudomonal activity of piperacillin\/tazobactam: more than a decade of experience from the SENTRY antimicrobial surveillance program (1997-2007). Diagn Microbiol Infect Dis. 2009;65(3):331\u20134.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-020-01109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-020-01109-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-020-01109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:02:24Z","timestamp":1620046944000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-020-01109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1186\/s13019-020-01109-y","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We obtained IRB approval for the study from our institution KFMC, with IRB NO:","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained for publication by IRB (Institution Review Board) of King Fahd Medical City and approved for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}